Last updated on August 2018

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Colorectal Cancer | head and neck cancer | Squamous Cell of Head and Neck | bladder cancer | Renal Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | Non-Small Cell Lung Cancer | Carcinoma | Breast Cancer | Gastric Adenocarcinoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients with histologically or cytologically-confirmed, locally advanced, or metastatic solid malignancy that is relapsed, refractory, or progressing following at least 1 prior systemic therapy (Part A)
  • Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1
  • Patients in Part B must have histologically or cytologically-confirmed, locally-advanced, or metastatic solid malignancy within the disease indications of Part A
  • Adequate baseline hematologic, renal, and hepatic function
  • Patients for whom there is no further standard therapy available at the time of enrollment (Part A)
  • Patients with a histologically-confirmed, advanced solid malignancy for which pembrolizumab is approved (Parts C and D)

Exclusion Criteria:

  • Patients with carcinomatous meningitis or active central nervous system (CNS) metastases
  • Patients with recent (within 14 days) or serious ongoing infection
  • Patients requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalents) or immunosuppressive medications within 14 days of enrollment
  • Patients with active known or suspected autoimmune disease or significant autoimmune-related toxicity from prior immuno-oncology therapy
  • Known active or latent tuberculosis
  • Uncontrolled diabetes mellitus
  • History of interstitial lung disease
  • Gastrointestinal abnormality that would affect absorption of SGN-2FF
  • Patients tested positive for hepatitis B or with a known, active hepatitis C infection
  • Women who are pregnant or breastfeeding

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.